tbuckley/cabot-search huggingface dataset:
Effects of small molecules on neurogenesis: Neuronal proliferation and differentiation
Authors: Michał K. Jastrzębski, Piotr Wójcik, Piotr Stępnicki, Agnieszka A. Kaczor
Journal: Acta Pharmaceutica Sinica B (2023)

Neurons are believed to be non-proliferating cells. However, neuronal stem cells are still present in certain areas of the adult brain, although their proliferation diminishes with age. Just as with other cells, their proliferation and differentiation are modulated by various mechanisms. These mechanisms are foundational to the strategies developed to induce neuronal proliferation and differentiation, with potential therapeutic applications for neurodegenerative diseases. The most common among these diseases are Parkinson's disease and Alzheimer's disease, associated with the formation of β-amyloid (Aβ) aggregates which cause a reduction in the number of neurons. Compounds such as LiCl, 4-aminothiazoles, Pregnenolone, ACEA, harmine, D2AAK1, methyl 3,4-dihydroxybenzoate, and shikonin may induce neuronal proliferation/differentiation through the activation of pathways: MAPK ERK, Pi3K/AKT, NFκB, Wnt, BDNF, and NPAS3. Moreover, combinations of these compounds can potentially transform somatic cells into neurons. This transformation process involves the activation of neuron-specific transcription factors such as NEUROD1, NGN2, ASCL1, and SOX2, which subsequently leads to the transcription of downstream genes, culminating in the transformation of somatic cells into neurons. Neurodegenerative diseases are not the only conditions where inducing neuronal proliferation could be beneficial. Consequently, the impact of pro-proliferative compounds on neurons has also been researched in mouse models of Alzheimer's disease.
807P Predicting surgical outcomes in patients with advanced ovarian cancer through MRI based preoperative evaluation
Authors: S. Liu, Z. Xu, X. Lv, Y. Tang, Y. Liu, X. Wang, G. Cao, Y. Fu, Z. Li, M. Wang, L. Li, Q. Guo
Journal: Annals of Oncology (2023)

Ovarian cancer (OC) is the most lethal gynecologic tumor and is characterized by a widespread metastasis in abdominal cavity. Accurate preoperative evaluation is important for the specification of surgical procedures and prediction of surgical outcomes.Currently, a variety of imaging techniques can be used for preoperative evaluation of ovarian cancer such as the Computed Tomography (CT) Suidan score. However, the Magnetic resonance imaging (MRI) based preoperative evaluation was not fully explored. Here, our study explores the feasibility of MRI as a preoperative assessment in OC patients. This is a prospective, non-randomized, single-center trial of 134 epithelial ovarian cancer (EOC) patients treated with surgical cytoreduction between 2018 and 2022. All patients underwent preoperative MRI scan. The imaging score consists of lesion size scores in 33 areas of the abdominal cavity. Complete cytoreduction (CC) was achieved in 81 (60.4%) of 134 patients. CC patients with a median MRI score of 10(4 - 44) and the median MRI score of patients who were incompletely cytoreduced (IC) was 15(5 - 48). By comparing imaging scores with those seen in surgery, we found that MRI evaluation is in good agreement with intraoperative observation. However, for areas such as the small bowel mesentery, the MRI score is lower than the intraoperative score, while for lymph node metastases the MRI score is higher than the intraoperative score. Through multi-factor analysis, we have screened clinical and imaging criteria related to IC including CA125 level, prognostic nutritional index (PNI), diaphragmatic surface of spleen lesion, gallbladder fossa lesion and small bowel mesentery lesion. Based on these criteria, we have constructed preoperative imaging scores and the 'predictive score' was assigned to each criterion based on its multivariate OR. Our research explores the feasibility of incorporating tumor load into MRI based preoperative assessment for OC patients. Also, we identified 5 criteria associated with IC, and developed a predictive model which may be helpful in treatment planning.
789P Real-world (RW) duration of treatment in first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC): CHAR1ZMA study
Authors: F. Backes, T. Boyle, J. Perhanidis, J. Lim, J. Hartman, J.M. Schilder, J. Hurteau, A. Golembesky, R. Salani
Journal: Annals of Oncology (2023)
613P Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Authors: G. Prager, J. Taieb, M. Fakih, F. Ciardiello, E. Van Cutsem, M.E. Elez Fernandez, F.J.S.M. Cruz, L.S. Wyrwicz, Z. Pápai, P.G. Poureau, G. Liposits, C. Cremolini, I. Bondarenko, D.P. Modest, E.M. Calleja, L. Roby, V. Barboux, N. Causse-Amellal, J. Tabernero
Journal: Annals of Oncology (2023)
90P Discovery of CMPD1 as a tumor-specific cytotoxic microtubule inhibitor
Authors: M. Takada, Y-C. Chen, J. Wang, H. Yamada, M. Yu, J. Sakakibara, H. Fujimoto, T. Nagashima, M. Ohtsuka, M. Takaku, A. Suzuki
Journal: Annals of Oncology (2023)
1550P Evaluating the novel combination of pressurized intraperitoneal aerosol chemotherapy-oxaliplatin (PIPAC-OX) as an immunomodulator in combination with systemic nivolumab for gastric cancer peritoneal metastases
Authors: R. Sundar, D. Chia, W. Ceelen, C. Chia, G. Kim, A. Shabbir, W. Willaert, J. Ong, J. Wong, C.J. Seo, H.L. Tan, E. Callebout, K. Geboes, M.C.H. Ng, J. Lum, W.Q. Leow, S. Selvarajan, A. Hoorens, W.P. Yong, J.B.Y. So
Journal: Annals of Oncology (2023)
921P HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer
Authors: L. Nabell, A.L. Ho, M.R. Posner, P. Neupane, A-R. Naqash, S. Wong, J.J. Niu, A.T. Pearson, D. Laux, D.R. Adkins, A. Pimentel, A.J. Rosenberg, D.L. Richardson, W. Wong, T.A. Kaufmann, K. Katchar, X. Qing, C. Iacobucci, K. Schlienger, D. Pfister
Journal: Annals of Oncology (2023)
1519P Fruquintinib plus sintilimab in patients (pts) with either treatment-naïve or previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results from a multicenter, single-arm phase II study
Authors: X. Wei, J. Li, H. Yuan, W. Zhang, W. He, P. Lu, H. Shi, P. Tan, S. Fan, M. Shi, W. Su, Y. Bai
Journal: Annals of Oncology (2023)
621P The systemic proteome of consensus molecular subtypes from patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial
Authors: A. Ballhausen, O. Shomroni, A. Stahler, B. Hoppe, M. Karthaus, S. Fruehauf, U. Graeven, G.M. Sommerhäuser, A.H.S. Alig, E. Goekkurt, J. Meyer-Knees, A. Kurreck, S. Held, S. Kasper-Virchow, V. Heinemann, S. Stintzing, T. Trarbach, M. Mülleder, M. Ralser, D.P. Modest
Journal: Annals of Oncology (2023)
1555P Cell-free DNA analysis in patients with metastatic gastroesophageal adenocarcinoma: Preliminary results of the REGIRI - PRODIGE 58 ancillary study
Authors: A. Harlé, A. Merigout, L. Evesque, A. Turpin, D. Tougeron, D. Botsen, M. Muller, C. de la Fouchardiere, O. Dubreuil, A. Zaanan, O. Bouche, M. Ben Abdelghani, S. Watson, S. Dermeche, F. Khemissa Akouz, M. Husson, J.L. Merlin, A-S. Bach, H. Senellart, E. Samalin-Scalzi
Journal: Annals of Oncology (2023)
1553P Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy: A randomized phase II proof-of-concept study
Authors: B. Doeve, D. Geijsen, M. van Berge Henegouwen, M. van Mourik, R.E. Pouw, N.C. van Grieken, S. Vrijaldenhoven, J-P. Medema, S. Derks, M.F. Bijlsma, H.W.M. van Laarhoven
Journal: Annals of Oncology (2023)
1549P A prospective study of circulating tumor DNA (ctDNA) genomic profiling in gastric or gastroesophageal junction (GEJ) cancer patients with recurrence after adjuvant chemotherapy: Liquid-GEAR trial
Authors: H. Takeda, R. Kawabata, A. Ishiguro, S. Nishina, M. Takahashi, S. Suzuki, T. Suzuki, J. Matsuyama, A. Okita, H. Miyagaki, N. Takegawa, T. Nomura, Y. Kito, H. Yabusaki, Y. Negoro, A. Makiyama, M. Nakamura, M. Takahashi, Y. Sunakawa
Journal: Annals of Oncology (2023)
818TiP REFRaME-O1/ENGOT-OV79/GOG-3086: A phase II/III open-label study evaluating the efficacy and safety of luveltamab tazevibulin versus investigator’s choice of chemotherapy in women with relapsed platinum-resistant epithelial ovarian cancer expressing folate receptor alpha (FolRα)
Authors: R.W. Naumann, A. Gonzalez Martin, T.J. Herzog, R.L. Coleman, I.L. Ray-Coquard, R. Miller, L. Lu, H. Dokainish, C. Berman, A. Oaknin
Journal: Annals of Oncology (2023)
605P First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort
Authors: H. Oliveres, V. Alonso-Orduna, J. Feliu, A. Fernandez Montes, M. Martin-Richard, E. Galvez Munoz, A. Ruiz-Casado, A. Yubero Esteban, J. Aparicio, J. Alcaide-Garcia, J. Gallego Plazas, A. Carmona-Bayonas, C. Fernandez Martos, M.R. Gallego, H. Manzano Alemany, R. Leno, F.M. Esposito, V. Sapena, J. Maurel
Journal: Annals of Oncology (2023)
821TiP Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis)
Authors: G.I. Shapiro, B. Basu, A.B. El-Khoueiry, S. Postel-Vinay, S-A. Im, S.Y. Rha, C.F. Friedman, A. Italiano, Y.M. Kim, M-C. Lim, R. Roux, J.F. Liu, M. Brown, B.W. Webb, N. Lukashchuk, E.J. Dean, J. Nehra, B. Loembé, M.G. Krebs
Journal: Annals of Oncology (2023)
796P Initial management and long-term outcome of advanced low-grade serous ovarian cancer (LGSOC) exploring role of surgery and maintenance therapy in the French multicentre ESME database
Authors: T. Papazyan, E. Martin, P. Pautier, C. Guerin-Charbonnel, E. Rowinski, F. Lecuru, F. Joly Lobbedez, T. De La Motte Rouge, C. Guillemet, H. Costaz, R. Sabatier, E. Barranger, P-E. Colombo, F. Marchal, C. Pomel, A.M. Savoye, L. Bosquet, L. Gladieff, C. Bourgin, J-S. Frenel
Journal: Annals of Oncology (2023)
1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)
Authors: M. Tehfe, J. Lee, S.Y. Rha, Y. Nakamura, J. Tabernero, K. Shitara, D-Y. Oh, J. Eads, J. Marshall, Z.A. Wainberg, K-W. Lee, Y-K. Kang, C-Y. Liao, S.Y. Oh, K-H. Yeh, D. Richards, M.M. Ubowski, K. Zhao, S. Bhaumik, J.H. Strickler
Journal: Annals of Oncology (2023)
802P Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
Authors: F. Marmé, F. Hilpert, M. Welslau, J.P. Grabowski, A. Schneeweiss, A.D. Hartkopf, S. Becker, I. Runnebaum, D. Bauerschlag, P. Fasching, C. Brandi, J-K. Rehbein, R. Glowik, J. Sehouli
Journal: Annals of Oncology (2023)
805P Tumor-informed ctDNA detection as a predictive marker for postoperative residual disease in epithelial ovarian cancer: A feasibility study
Authors: C. Grimm, V. Paspalj, M. Postl, L. Saal, C. Brueffer, N. Segui Gracia, M. Alcaide, S. Polterauer, L. Oton, Y. Chen, G. Hofstetter, L. Müllauer
Journal: Annals of Oncology (2023)
1522P Camrelizumab plus chemotherapy versus concurrent chemoradiotherapy as neoadjuvant therapy for resectable thoracic oesophageal squamous cell cancer (REVO): A multicenter, randomized, open-label, phase II trial
Authors: W.P. Yuan, Y. Chen, J. Liu, W. Zhang, X. Chen, H. He, P. Chen, J-P. Lin, D. Zhang, H. Lin, W. Wei, W. Chen, H. Zhou, P. Gao, S. Liu, F. Wang
Journal: Annals of Oncology (2023)
1517P Patient-related outcomes (PROs) after early palliative care (PC) (EPC) compared with standard oncologic care (SOC) for patients (pts) with metastatic upper gastrointestinal cancers (mUGIC): Results of the randomised EPIC trial
Authors: A. Da Silva, A. Adenis, E. Bogart, P. Chiappa, M. Paul, D. Pannier, L. Huffman-Touzet, H. Gaillard-Pereira, A. Henry, E. Samalin-Scalzi, J.E. Kurtz, D. Cornuault-Foubert, H. Delmarre Van Damme, A. Proux, M.P. Galais, V. Bourgeois, C. Belletier, J. Wallet, G. Chvetzoff, M-C. Le Deley
Journal: Annals of Oncology (2023)
866P Prognostic performance of a genome-wide methylome enrichment platform in head and neck cancer
Authors: G. Liu, J. Zhang, O. Hall, J. Bergener, Y. Wang, B. Brown, J. Min, S.Y. Shen, M. Pienkowski, S.H. Huang, L. Ailles, A. Polio, E. Sosa, S. Bratman, B. Allen, K. Brown, A. Licon, A-R. Hartman, D.D. De Carvalho, B. Ho Park
Journal: Annals of Oncology (2023)
870P Dynamic cfHPV DNA changes during induction chemotherapy as an early indicator of treatment responsiveness for locally advanced head and neck cancer patients
Authors: Y. Cao, A.P. Kiess, M. Hwang, K. Boudadi, V. Saloura, A.K. Mattox, E. Gramiccioni, D. Schmitt, J. Swindell, A. Starus, F.S. Jones, H. Quon, T. Seiwert
Journal: Annals of Oncology (2023)
616P Sequential treatment with regorafenib (REG) and trifluridine/tipiracil (TAS) +/- bevacizumab (Bev) in refractory metastatic colorectal cancer (mCRC) in community clinical practice in the USA
Authors: T. Bekaii-Saab, D. Ahn, C. Yuan, X. Jiao, M. Kurtinecz, X. Pan, Z. Vassilev, H. Ostojic
Journal: Annals of Oncology (2023)
89P Cold atmospheric plasma-activated fluids as a potential new intravesical agent for the treatment of bladder cancer
Authors: M.F. Botelho, E. Tavares-da-Silva, E. Pereira, J. Craveiro, L. Fernandes, F. Caramelo, A.M. Abrantes, A.S. Pires, A. Figueiredo
Journal: Annals of Oncology (2023)
820TiP A randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance (KGOG 3067/SOCCER-P trial)
Authors: H-W. Cho, J-W. Kim, J-Y. Park, Y-Y. Lee, M-C. Lim, S. Lee, K-J. Min, K.J. Eoh, K.B. Lee, M.K. Kim, J.Y. Song, S-H. Shim, Y.I. Ji, Y-J. Song, J-Y. Lee
Journal: Annals of Oncology (2023)
1556P Pharmacokinetics, pharmacodynamics and exposure response analyses of osemitamab in patients with locally advanced or metastatic solid tumors
Authors: L. Shen, J. Yao, D. Chen, M. Yu, X-A. Lin, C. Qi, Z. Xia, L. Zhang, S. Yu, C. Germa
Journal: Annals of Oncology (2023)
61P Next generation sequencing and its clinical utility in advanced cancer: Single institute experience from low-middle income country
Authors: A. Badola, P. Bansal, P. Mehta, M. Malhotra, S.C. Cheemala, S. Sood, S. Anand, V. Sekar, P. Singh, J. Verma, A. Zaidi
Journal: Annals of Oncology (2023)
859MO Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial
Authors: L. Michel, A. Jimeno, A. Sukari, T. Beck, J.W.Y. Chiu, E.S. Ahern, J. Hilton, None A. Hollebecque, S. Zanetta, J. Patel, S. Mekan, T. Wu, E.E. Dumbrava
Journal: Annals of Oncology (2023)
1543P Clinical study of camrelizumab combined with docetaxel and carboplatin in neoadjuvant treatment of locally advanced oesophageal squamous cell carcinoma
Authors: R. Wang, G. Zhang, Q. Zhu, T. Ma, C. Weng, D. Zhang, H. Zeng, T. Wang, F. Gao, L. Mi
Journal: Annals of Oncology (2023)
858O Minimal residual disease (MRD) diagnosed by a plasma tumor-agnostic circulating tumor DNA (ctDNA) assay after curative therapy in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) predicts disease relapse and survival
Authors: N. Honoré, C. Van Marcke de Lummen, R. Galot, R. Helaers, A. van Maanen, J. Ambroise, A. Mendola, H. Dahou, E. Marbaix, P. van Eeckhout, E. Longton, M. Magremanne, S. Schmitz, N. Limaye, J-P. Machiels
Journal: Annals of Oncology (2023)
1540P Tislelizumab combined with neoadjuvant chemoradiotherapy for resectable locally advanced oesophageal squamous cell carcinoma: A prospective, phase II clinical study
Authors: Y. Zhang, Y. Yuan, Y. Xu, R. Tian, J. Liao, X. Zeng, Y. Wang, Y. Liu, X. Zhou, F. Peng, L. Zhou, H. Wang, W. Hou, M. Yu, W. Xiu, M. Huang, X. Zhang, Y. Gong, Y. Lu, B. Zou
Journal: Annals of Oncology (2023)
781P Chemotherapy sensitivity score based on ex vivo 3D tumour testing to predict clinical response for ovarian cancer patients
Authors: J. Walraven, C.D. de Kroon, A. van Altena, D. van der Meer, L. Ceton, J. van der Valk, T. Sijsenaar, F. Grillet, M. Garcia Montero, W. Vader, P.B. Ottevanger, J.R. Kroep
Journal: Annals of Oncology (2023)
1552P Clinical multi-omics analysis of gastric cancer (GC) in Europe (EU) and Latin America (LatAm): The LEGACy project
Authors: T.C. Fleitas, F. Ruiz-Pace, T. van Schooten, R. Barros, E. Fernandez-Figueroa, M. Alsina Maqueda, A. Riquelme, C. Martinez Ciarpaglini, A. Miralles, E. Jimenez, C. Caballero, H. Boggino, E. Ruiz, J. Farrés, F. Esteso, S. Derks, C. Figuereido, F. Carneiro, R. Dienstmann, A. Cervantes
Journal: Annals of Oncology (2023)
85P In silico evaluation of the transcriptomic and immunologic profile of lung adenocarcinomas with deletions or disruptive mutations of SMARCA4
Authors: E. Garcia Lorenzo, C. Nieto-Jimenez, C. Diaz-Tejeiro, B. Doger de Spéville, I. Moreno, M. Pedregal, L. Paniagua Herranz, A. Sanvicente, B. Gyorffy, V. Moreno Garcia, E. Calvo, A. Ocana Fernandez
Journal: Annals of Oncology (2023)
1521P Addition of durvalumab to CROSS in oesophageal adenocarcinoma is feasible and safe
Authors: H. Schloesser, A. Lohneis, M.A. Garcia-Marquez, M. Thelen, P. Schiller, M. von Bergwelt, A. Hillmer, W. Schroeder, M.J. Hallek, A. Quaas, C. Bruns, T. Zander
Journal: Annals of Oncology (2023)
1583P Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: A systematic review and meta-analysis
Authors: N.A.D. Guchelaar, K. Nasserinejad, B. Mostert, S.L. Koolen, P.C. van der Sluis, S.M. Lagarde, B.P.L. Wijnhoven, R.H. Mathijssen, B.J. Noordman
Journal: Annals of Oncology (2023)
CN3 Patient adherence to digital patient-reported outcome monitoring (PROM) in cancer immunotherapies
Authors: J. Lijnsvelt, S.G. Aanes, S.M.E. Iivanainen, M.G. Vitale, S. Mentu, R. Arokoski, P. Mohr, A. Addeo, P.A. Ascierto, J.P. Koivunen, E.C. Haukland, C.U. Blank
Journal: Annals of Oncology (2023)
1566P Clinical relevance of circulating tumor DNA in HER2 -positive advanced gastric cancer: Results from phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High)
Authors: H. Osumi, T. Wakatsuki, D. Takahari, A. Ooki, K. Chin, H. Shoji, M. Ogura, I. Nakayama, N. Yamamoto, H. Hirano, H. Hara, K. Minashi, E. Shinozaki, K. Kato, N. Kurihara, S. Kitano, K. Takeuchi, N. Boku, K. Yamaguchi
Journal: Annals of Oncology (2023)
788P Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches
Authors: F. Blanc-Durand, C. Kramer, E. Rouleau, D. Vasseur, T. Bosse, S. de Boer, R. Edmondson, M. Powell, E. Crosbie, N. Singh, J. McAlpine, H. Mackay, P. Pollock, L. Mileshkin, C.L. Scott, N.Y.L. Ngoi, Y.W. Lim, S.E. Lim, D.S. Tan, A. Leary
Journal: Annals of Oncology (2023)
1567P The effect of SGLT2i and DPP4i on new-onset gastric cancer and gastric diseases in type 2 diabetes mellitus: A population-based cohort study
Authors: H.I. Chou, V.K. Chauhan, L. Lu, C.T. Chung, T.T.L. Lee, S. Lee, H. Liu, T.K.R. Pang, A. Kaewdech, B. Cheung, G. Tse, J. Zhou
Journal: Annals of Oncology (2023)
771P Genomic characterization of advanced endometrial carcinosarcoma: Identification of potentially actionable targets
Authors: U.F.F. De Giorgi, Z. Kuang, N.A. Danziger, J.A. Moore, D.I. Lin, G. Mangili, S. Pignata, E.S. Sokol, S. Sivakumar
Journal: Annals of Oncology (2023)
1536P HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+ advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome
Authors: J. Tobias, M. Kundi, E. Garner-Spitzer, C. Zielinski, M. Maglakelidze, Z.G. Andric, Z. Petrovic, R. Nagarkar, T. Chawla, L.O. Chong, B. Nixon, S. Yavrom, N. Ede, U. Wiedermann
Journal: Annals of Oncology (2023)
77P Normative data on the sexual health questionnaires - QLQ-SHQ22, and the sexual domains of the QLQ-BR23/BR45 - for Norwegian general population with and without cancer
Authors: R.E. Åsberg, G. Giskeødegård, M.J. Hjermstad, K.V. Reinertsen, J. Karlsen, M. Nilsen, R.J. Reidunsdatter
Journal: Annals of Oncology (2023)
615P The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer
Authors: S. Yuki, K. Harada, T. Kawakami, T. Ogata, Q. Hu, K. FUSHIKI, K. Oshima, S. Kadowaki, H. Taniguchi, K. Muro, R. Nakanishi, K. Ando, S. Nambara, T. Nakamura, Y. Kawamoto, Y. Komatsu, E. Oki, T. Masuishi, K. Yamazaki
Journal: Annals of Oncology (2023)
618P Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer
Authors: T.W. Kim, K-W. Lee, J.B. Ahn, Y.S. Hong, S.Y. Kim, J.W. Kim, J-W. Kim, S.J. Shin, S.H. Beom, S.T. Kim, J. Lee, H. Kim, S-J. Kim, Y.S. Park
Journal: Annals of Oncology (2023)
775P A gene expression signature to predict benefit from intraperitoneal (IP) carboplatin chemotherapy in ovarian carcinoma (OC): Translational research study from the intraperitoneal therapy for ovarian cancer with carboplatin (iPocc) phase II/III trial
Authors: D.S. Tan, T.Z. Tan, J. Ye, N.Y.L. Ngoi, A. Ogasawara, D. Shintani, A. Kurosaki, K. Yamamoto, Y-H. Jan, S-J. Chen, K. Fujiwara, R. Huang, K. Hasegawa
Journal: Annals of Oncology (2023)
1530P Health-related quality of life (hrqol) in patients with claudin-18 isoform 2-positive (CLDN18.2+) locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma: Results from SPOTLIGHT and GLOW
Authors: F. Lordick, E. Van Cutsem, K. Shitara, R-H. Xu, J.A. Ajani, M.A. Shah, M. Oh, A. Ganguli, S. Rhoten, P. Bhattacharya, M. Matsangou, J.W. Park, Y-K. Kang
Journal: Annals of Oncology (2023)
806P Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers
Authors: A. Madariaga Urrutia, N. Jivraj, P. Soberanis Pina, F. Somji, T. Truon, S. Melwani, M. Lovas, G. Bhat, H.A. Alqaisi, E. Gonzalez-Ochoa, A.C. Veneziani, N.C. Dhani, R. Grant, V. Bowering, A.M. Oza, L. Wang, A. Berlin, S. Lheureux
Journal: Annals of Oncology (2023)
6P Combined single-cell and spatially resolved mapping of the human lymph node ecosystem reveals fundamental principles of lymphoma tissue organization
Authors: D. Hübschmann, L. Jopp-Saile, F. Czernilofsky, A. Mathioudaki, R. Lutz, D. Vonficht, X. Wang, M.A. Baertsch, H. Vöhringer, T. Roider, J. Mammen, D. Ordoñez-Rueda, C. Pabst, W. Huber, A. Trumpp, C. Müller-Tidow, G. Nolan, J. Zaugg, S. Haas, S. Dietrich
Journal: Annals of Oncology (2023)
1511O Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study
Authors: Y.Y. Janjigian, A. Kawazoe, Y. Bai, J. Xu, S. Lonardi, J-P. Metges, P.E. Yanez Weber, L.S. Wyrwicz, L. Shen, Y.V. Ostapenko, M. Bilici, H.C. Chung, K. Shitara, S. Qin, E. Van Cutsem, J. Tabernero, K. Li, C-S. Shih, P. Bhagia, S.Y. Rha
Journal: Annals of Oncology (2023)
609P The impact of surgical invasiveness on the efficacy of mFOLFOX6 in resected colorectal liver metastasis: An exploratory analysis of JCOG0603
Authors: Y. Takamizawa, K. Kataoka, J. Mizusawa, Y. Shimizu, Y. Inaba, M. Ohue, K. Komori, A. Shiomi, M. Shiozawa, J. Watanabe, T. Suto, Y. Kinugasa, Y. Takii, H. Bando, T. Kobatake, M. Inomata, K. Danno, M. Ito, H. Ojima, Y. Kanemitsu
Journal: Annals of Oncology (2023)
5P Tertiary lymphoid structures (TLS) presence and stromal blood vessels heterogeneity differentially influence recurrence, lymphovascular, and perineural invasion in breast cancer molecular subtypes
Authors: A.A. Cosma, A.C. Barb, S.M. Negru, M.M. Pasca Fenesan, A.M. Cimpean
Journal: Annals of Oncology (2023)